MNPR (27) FTH (29) EOLS (27) CTMX (14) ⌘ Pro Terminal →

BlossomHill Therapeutics Inc. (BLSM) — RQD Stock Rating Cockpit

$13.75 -9.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.49

BlossomHill Therapeutics Inc. (BLSM) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $483.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BLSM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BLSM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, BlossomHill Therapeutics Inc. (NASDAQ: BLSM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $13.75 (-9.60% 1D, market cap $483.4M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BLSM compare to MNPR and FTH in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BLSM carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MNPR (Monopar Therapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -17.4%, cap $482.7M) and FTH (Faeth Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $484.5M). Among the 5-stock peer group, BLSM leads on earnings multiple (N/A) while MNPR leads on capital efficiency (-17.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BLSM?

▼

Per BLSM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001839970), BlossomHill Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $163.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $13.49 (-1.92%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BLSM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY BLSM SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0.3% FCF Margin ($13.5M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$17.27-18% Next Q

Q2 (-2Q)

Grade D$14.16+15.7% Next Q

Q3 (-1Q)

Grade D$16.39-16.1% Next Q

Current

Grade D-$13.75-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BLSM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BLSM currently carries a cautious 42/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.95) and Max Pain ($14.44) forces dealer call-delta covering toward $29.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BLSM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BLSM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

44.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE5% OF RANGE

L: $13$13.75H: $28

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on BLSM

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (50)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (32)

12/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like BLSM

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BLSM)

✓Walkthrough of BLSM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BLSM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.06%▼ DESCENDING CHANNEL

2026-11-02O $16.46H $16.46L $13.75C $13.75VOL 99.0K

RES: $17.21SUP: $9.92SMA50: $18.95SMA200: $18.46

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BLSM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BLSM Butterfly Map → + Track BLSM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BLSM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BLSM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BLSM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BLSM)

Health Care Rank #472 of 1016 ⚔️ MNPR vs BLSM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BLSM vs. MNPR, FTH, EOLS, CTMX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BlossomHill Therapeutics Inc. (BLSM) ranks #472 by composite RQD confidence (42/100, grade D-) and #459 by equity capitalization ($483.4M). Within this direct 5-issuer industry benchmark cohort, BLSM leads on earnings valuation at N/A trailing P/E, while MNPR leads on capital efficiency and profitability with -17.4% ROIC and — gross margin. BLSM currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BLSM ACTIVE BlossomHill Therapeutics Inc.	D-	42/100	—	—	—	-9.60%	$483.4M	Benchmark Subject
MNPR Monopar Therapeutics Inc.	E	27/100	—	—	-17.4%	-2.21%	$482.7M	/mnpr-vs-blsm →
FTH Faeth Therapeutics Inc.	E	29/100	—	—	-35.0%	-0.32%	$484.5M	/fth-vs-blsm →
EOLS Evolus Inc.	E	27/100	—	66.3%	-35.0%	-2.26%	$496.7M	/eols-vs-blsm →
CTMX CytomX Therapeutics Inc.	E	14/100	—	—	-20.5%	+2.18%	$499.0M	/ctmx-vs-blsm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001839970

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BlossomHill Therapeutics Inc. (BLSM) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, BLSM closed FY2025 with $163.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$163.0M	—

3. BLSM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BLSM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BLSM compare to MNPR and FTH in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BLSM?

Where is BLSM trading relative to its 50-day, 200-day, and 52-week technical levels?

BLSM last traded at $13.75 (-9.60% on volume of 156,302 shares), positioning the stock -27.44% below its 50-day simple moving average ($18.95) and -25.51% below its 200-day simple moving average ($18.46). Across its 52-week range of $12.93 to $27.99, BLSM sits at the 5.4% percentile with a 14-day RSI of 44.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($12.03 to $15.47).

BLSM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell BLSM stock right now?

BlossomHill Therapeutics Inc. (BLSM) currently earns a Roarable Rating of D- (Sell — SELL) with 42/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is BLSM's 12-month price target and RQD AI Jury consensus?

BLSM's 12-month base price target is $12.76 (range $9.95 to $29.39), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: BLSM RQD Cockpit BLSM 12M Forecast BLSM Earnings & Move BLSM Dividends & DRIP BLSM Insiders & 13F BLSM Whale Options BLSM Profit Sankey BLSM News & Why

ROARABLE RATING BRIEF • RQD 42/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BLSM — BlossomHill Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:15:58Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BLSM scores 42 out of 100, a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:

Fundamental Cash Engine: 10 / 20 (ROIC 0%; FCF yield 0%). The rating reflects no measurable return on invested capital and no free-cash-flow yield in the source data, which means the business is not currently generating a cash return an investor could point to.
Whale / 13F Flow: 3 / 20 (institutional accumulation and options positioning). This is the weakest pillar. The holders section contains no institutional or options data, so the low score signals an absence of supportive smart-money flow rather than documented selling.
Insider Conviction: 9 / 20 (SEC Form 4 and Congressional PTR cluster flow). The source data contains no insider or Congressional trade records; the score is low on the basis of the rating's inputs.
Macro Regime Fit: 7 / 20 (Beta 1.0; sector sensitivity). A beta of 1.0 means the stock is expected to move in line with the market, and the rating treats that exposure as a modest negative given current conditions.
Forensic Balance Sheet: 13 / 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). This is the strongest pillar, and it is the main reason the score is not lower. The balance sheet metrics are moderate rather than distressed.

For a prospective investor evaluating the stock today, the practical takeaway is that the rating is driven by the absence of earnings, cash return, and supportive institutional or insider flow, partly offset by a balance sheet that is not flagged as distressed. Valuation cannot be assessed from the source data because P/E and EV/EBITDA are unavailable, so the rating should be read as a statement about current fundamentals and flow rather than a price-target judgment.

Business

BlossomHill Therapeutics Inc. (BLSM) is a NASDAQ-listed company in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations, per the company profile. The profile does not describe its specific products, customers, or revenue model. Per the SEC financials, reported revenue for FY 2025 is $0.0M, so the source data does not show a revenue-generating operation in the period covered. Not available in source data: product portfolio details, customer base, and monetization structure.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025 (filed 2025-12-31)	$0.0M	$0.0M	$0.0M	N/A	N/A	$136.7M	N/A

Per the SEC financials, the company reported no revenue, operating income, or net income for FY 2025, and margins are recorded as 0% across gross, operating, and net. ROIC is 0% per the market data. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6 out of 9, with a Debt/Equity ratio of 0.5. Reported cash of $136.7M is the main balance-sheet figure in the source data, while debt is recorded as N/A.

Recent Catalysts & News Wire Analysis

Per the recent news wire, the most material item is a GlobeNewswire release announcing a collaboration with Foundation Medicine to develop a first companion diagnostic for BH-30643 in EGFR C797S mutated non-small cell lung cancer. This is the only item in the source data describing a clinical or commercial development. The remaining items are market-action reports from Seeking Alpha, MarketBeat, and TradingView, all flagged "RISK WATCH" with a red signal, covering share price declines and an average target price of $35.00.

Per the Butterfly Supply-Chain Graph, there is one proprietary signal: a LIQUIDITY_TAILWIND of bearish direction with a severity score of 94. Its terminal label is a Macro Tailwind Score of 18 out of 100. The signal reports True Net Liquidity falling -0.64% over four weeks to $5,746B, an elasticity of 6.00x beta, and a 2 bps widening in HY OAS, with a correlation of r=+0.17 and a z-score of 6.1. These are macro-liquidity readings and do not describe company-specific events.

Open Questions

What are BlossomHill's revenue sources and expected timeline to commercialization for BH-30643, given that FY 2025 revenue is reported at $0.0M?
What is the company's cash runway, given $136.7M of reported cash and no reported operating income or debt figure?
Why is the Forward P/E, EV/EBITDA, and EPS unavailable, and would earnings-based valuation become possible?
Who holds the stock institutionally, and what is the 13F and options positioning behind the 3 / 20 whale-flow pillar?
What does the companion diagnostic collaboration with Foundation Medicine mean financially and on what timetable?

BLSM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BlossomHill Therapeutics Inc. (BLSM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BLSM Debate Forum (3) ↓

🔴 RISK WATCH Seeking Alpha • 8h ago

BlossomHill Therapeutics: A Deliberate Beachhead Trading Back At Its IPO Price (BLSM)

Seeking Alpha report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH MarketBeat • 11h ago

BlossomHill Therapeutics (NASDAQ:BLSM) Shares Down 6.6% - Here's What Happened

MarketBeat report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH TradingView • 14h ago

BlossomHill Therapeutics, Inc. Estimates – NASDAQ:BLSM

TradingView report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH MarketBeat • 17h ago

BlossomHill Therapeutics (NASDAQ:BLSM) Stock Price Down 7% - What's Next?

MarketBeat report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH GlobeNewswire • 20h ago

BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer

GlobeNewswire report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH MarketBeat • 23h ago

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Stock Has Average Target Price of $35.00

MarketBeat report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH MarketBeat • 1d ago

BlossomHill Therapeutics (NASDAQ:BLSM) Shares Up 8.1% - Should You Buy?

MarketBeat report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 1d ago

BlossomHill Therapeutics (NASDAQ:BLSM) Upgraded to Hold at Wall Street Zen

MarketBeat report covering BlossomHill Therapeutics Inc. (BLSM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BLSM Bull vs. Bear Conversation Board — What's Your Call at $13.75?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BLSM 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $13.38 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BLSM (D- • RQD 42/100) a Buy at $15.21?

Welcome to the BLSM (BlossomHill Therapeutics Inc.) Roar Pit. Current RQD Composite is 42/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $12.32 (-19.0%)

Spot @ $15.21

Pump the brakes on BLSM — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BLSM, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless BlossomHill Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $17.80 (+17.0%)

Spot @ $15.21

BLSM cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BLSM, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $15.21 (52-wk range $12.93 - $27.99), any beat on forward guidance forces shorts and underweight funds to chase.